ABVC BioPharma (ABVC) Issues ADHD Phase II Part 2 Clinical Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to ABVC BioPharma (ABVC) Issues ADHD Phase II Part 2 Clinical Update

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

July 13, 2022 8:30 AM EDT

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase II Part II clinical study of the Companys ADHD medicine (ABV-1505). Since results on the first subject treated were reported on May 10, 2022, a total of 22 subjects have... More